

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPAL600RKA

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

***** Welcome to STN International *****

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 DEC 01 ChemPort single article sales feature unavailable
NEWS 3 JAN 06 The retention policy for unread STNmail messages
will change in 2009 for STN-Columbus and STN-Tokyo
NEWS 4 JAN 07 WPIDS, WPINDEX, and WPIX enhanced Japanese Patent
Classification Data
NEWS 5 FEB 02 Simultaneous left and right truncation (SLART) added
for CERAB, COMPUAB, ELCOM, and SOLIDSTATE
NEWS 6 FEB 02 GENBANK enhanced with SET PLURALS and SET SPELLING
NEWS 7 FEB 06 Patent sequence location (PSL) data added to USGENE
NEWS 8 FEB 10 COMPENDEX reloaded and enhanced
NEWS 9 FEB 11 WTEXTILES reloaded and enhanced
NEWS 10 FEB 19 New patent-examiner citations in 300,000 CA/CAPLUS
patent records provide insights into related prior
art
NEWS 11 FEB 19 Increase the precision of your patent queries -- use
terms from the IPC Thesaurus, Version 2009.01
NEWS 12 FEB 23 Several formats for image display and print options
discontinued in USPATFULL and USPAT2
NEWS 13 FEB 23 MEDLINE now offers more precise author group fields
and 2009 MeSH terms
NEWS 14 FEB 23 TOXCENTER updates mirror those of MEDLINE - more
precise author group fields and 2009 MeSH terms
NEWS 15 FEB 23 Three million new patent records blast AEROSPACE into
STN patent clusters
NEWS 16 FEB 25 USGENE enhanced with patent family and legal status
display data from INPADOCDB
NEWS 17 MAR 06 INPADOCDB and INPAFAMDB enhanced with new display
formats
NEWS 18 MAR 11 EPFULL backfile enhanced with additional full-text
applications and grants
NEWS 19 MAR 11 ESBIOBASE reloaded and enhanced
NEWS 20 MAR 20 CAS databases on STN enhanced with new super role
for nanomaterial substances
NEWS 21 MAR 23 CA/CAPLUS enhanced with more than 250,000 patent
equivalents from China
NEWS 22 MAR 30 IMSPATENTS reloaded and enhanced
NEWS 23 APR 03 CAS coverage of exemplified prophetic substances
enhanced
NEWS 24 APR 07 STN is raising the limits on saved answers

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN customer agreement. This agreement limits use to scientific research. Use for software development or design, implementation of commercial gateways, or use of CAS and STN data in the building of commercial products is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 08:09:35 ON 17 APR 2009

=> fil reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.22

0.22

FILE 'REGISTRY' ENTERED AT 08:10:02 ON 17 APR 2009

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 15 APR 2009 HIGHEST RN 1135193-69-9

DICTIONARY FILE UPDATES: 15 APR 2009 HIGHEST RN 1135193-69-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.


Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stdnoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\QUERIES\10511065.str



```

chain nodes :
1  2  3  4  5  6  13  14  15
ring nodes :
7  8  9  10  11  12
chain bonds :
1-14  2-13  2-3  2-14  3-4  4-5  4-7  5-6  5-15
ring bonds :
7-8  7-12  8-9  9-10  10-11  11-12
exact/norm bonds :
1-14  2-13  2-3  2-14  3-4  4-5  4-7  5-6  5-15  7-8  7-12  8-9  9-10  10-11  11-12

```

```

Match level :
1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:CLASS
10:CLASS 11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS


```

L1 STRUCTURE UPLOADED

=> d

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 08:10:47 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 220 TO ITERATE

100.0% PROCESSED 220 ITERATIONS

1 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 3511 TO 5289

PROJECTED ANSWERS: 1 TO 80

L2 1 SEA SSS SAM L1

=> s l1 full

FULL SEARCH INITIATED 08:10:50 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 4430 TO ITERATE

100.0% PROCESSED 4430 ITERATIONS

34 ANSWERS

SEARCH TIME: 00.00.01

L3 34 SEA SSS FUL L1

=> s l3 and caplus/lc

65189794 CAPLUS/LC

L4 32 L3 AND CAPLUS/LC


=> s l3 not l4

L5 2 L3 NOT L4

=> d 15 1-2

L5 ANWEX 1 OF 2 REGISTRY COPYRIGHT 2009 ACS on STN
 RN 1617919-49-1 REGISTRY
 ED Entered STN: 12 Dec 2009
 CN 2-*apetidine*carboxylic acid, 1-[(2*S*,3*S*)-2-(4-chlorophenyl)-3-
 [(3*S*)pyrazin-5-yl]carboxyl]-1-oxopentyl]-, (2*S*)- (CA INDEX NAME)
 TS STEREOISOMER
 MF C18 H21 Cl N2 O5
 SB Online Source
 Database: ChemSpider (ChemCo, Inc.)


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 ANWEX 2 OF 2 REGISTRY COPYRIGHT 2009 ACS on STN
 RN 61840-63-8 REGISTRY
 ED Entered STN: 05 Nov 2002
 CN 1-Pipetazimbutanamide, β-(4-chlorophenyl)-α-ethyl-1-*N*-hydroxy-2-
 [(12-methylpyrazolyl)amino]carbonyl]-γ-oxo-, (8*S*,10*S*,2*S*)-
 (CA INDEX NAME)
 TS STEREOISOMER
 MF C21 H23 Cl N4 O4
 CI CWH
 SB CA

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

=> fil caplus		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	197.25	197.47

FILE 'CAPLUS' ENTERED AT 08:13:09 ON 17 APR 2009
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 17 Apr 2009 VOL 150 ISS 17
 FILE LAST UPDATED: 16 Apr 2009 (20090416/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d his

(FILE 'HOME' ENTERED AT 08:09:35 ON 17 APR 2009)

FILE 'REGISTRY' ENTERED AT 08:10:02 ON 17 APR 2009

L1	STRUCTURE UPLOADED
L2	1 S L1
L3	34 S L1 FULL
L4	32 S L3 AND CAPLUS/LC
L5	2 S L3 NOT L4

FILE 'CAPLUS' ENTERED AT 08:13:09 ON 17 APR 2009

=> s l4

L6	7 L4
----	------


=> d ibib abs hitstr 1-7

16 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2004:761946 CAPLUS
 DOCUMENT NUMBER: 145:156719
 TITLE: Rapid Assembly of Matrix Metalloproteinase Inhibitors Using Click Chemistry
 AUTHOR(S): Wang, Juy; Chanchandana, Mahab, L.; Jung, B.; Minyng; Yao, Shao Q.
 CORPORATE SOURCE: Department of Chemistry and Biological Sciences, Medical Research Program of the Office of Life Sciences, National University of Singapore,
 Singapore,
 117543, Singapore
 SOURCE: Organic Letters (2004), 8(17), 2921-2924
 CSDN ORFITY IJEN: 1573-1062
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 CROSS SOURCE(S): CASREACT 145:156719
 AS A panel of 36 metalloproteinase inhibitors was assembled using click chemical

by reacting eight zinc-binding hydroxamate warheads with 12 azide building blocks. Screens of the intermediate compounds against representative metalloproteinases provided discerning inhibition fingerprints, revealing compounds with low micromolar potency against MMP-1. The relative ease and convenience of the strategy in constructing focused chemical libraries for rapid in situ screening of MMPs is thereby demonstrated.


IT 61015-27-29
 RI: KCT (Reactant); SPB (Synthetic preparation); FEP (Preparation); RACT (Reactant or reagent)
 (rapid assembly of triazolethioamide derivs. as matrix metalloproteinase inhibitors using click chemical)

RI 61015-27-2 CAPLUS
 CN 3-O-methylthiothioamide, β -glycylphenyl- γ -dioxo- β -[4-methoxyphenyl]- (CA INDEX NAME)




REFERENCE COUNT: 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

16 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




RI 612840-66-1 CAPLUS
 CN 2-ageradinebutanamide, N-hydroxy-N-(hydroxymethyl)- β -(4-methoxyphenyl)- α -(1-methylamino)carboxyl-1-glyoxo-, (4S,5S,2S)- (CA INDEX NAME)

Absolute stereochemistry.



RI 612840-67-2 CAPLUS
 CN 2-ageradinebutanamide, N-hydroxy-N-(hydroxymethyl)- β -(4-methoxyphenyl)- α -(1-methylamino)carboxyl-1-glyoxo-, (4S,5S,2S)- (CA INDEX NAME)


Absolute stereochemistry.



RI 888490-49-1 CAPLUS
 CN 1-piperidinobutanamide, N-hydroxy- β -(4-methoxyphenyl)- γ -oxo- α -(1,4,4-trimethyl-2,3-dioxo-2-imidazolidinyl)methyl-, (4S,5S)- (CA INDEX NAME)

Absolute stereochemistry.

16 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2004:315131 CAPLUS
 DOCUMENT NUMBER: 145:150401
 TITLE: A cassette-dosing approach for improvement of oral bioavailability of dual TACE/MMP inhibitors
 AUTHOR(S): Jansen, Philipp; Humann, Hif; Mully, Wolfgang; Pfeil, Roland; Ruhl, Thomas
 CORPORATE SOURCE: Novartis Institutes for Biomedical Research, Basel, CH-4002, Switzerland
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2006), 16(10), 2632-2636
 CSDN: 882340; IJEN: 0960-894X
 PUBLISHER: Elsevier B.V.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 145:20401
 CI



AS The structural features contributing to the different pharmacokinetic properties of the TACE/MMP inhibitors THF484 and Trocade were analyzed using an in vivo cassette-dosing approach in rats. This enabled us to identify a new lead compound (II) with excellent pharmacokinetic properties.


We weaker activity on the bind. targets. Directed structural modifications maintained oral bioavailability and restored anal.

activity, leading to a novel compound (II) almost equivalent to THF484 in vivo, but with a more than tenfold higher oral bioavailability.

IT 612840-61-49 612840-64-12 612840-67-29
 RI: PAC (Pharmacokinetic activity); RCT (Pharmacokinetic); SPB (Synthetic preparation); THF (Therapeutic use); ROL (Biological study); FEP (Preparation); DES (Use)
 (cassette-dosing approach for improvement of oral bioavailability of dual TACE/MMP inhibitors)


RI 612840-61-6 CAPLUS
 CN 1-piperidinobutanamide, N-hydroxy- α -(hydroxymethyl)- β -(4-methoxyphenyl)- γ -oxo-, (4S,5S)- (CA INDEX NAME)
 Absolute stereochemistry.

16 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RI 888490-50-4 CAPLUS
 CN 1-piperidinobutanamide, N-hydroxy- α -(hydroxymethyl)- β -(4-chlorophenyl)- ϵ -ethyl-N-hydroxy-2-(1-methylamino)carboxyl-1-glyoxo-, (4S,5S,2S)- (CA INDEX NAME)


Absolute stereochemistry.



REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT


PARTNO	NO	KIND	DATE	APPLICATION	NO	DATE
MO	005004041	A	20030128	MO	005004041	20030408
MO	005004048	A	20040325			
MO	005004050	AL	20030128	MO	005004050	20030408
MO	005004051	AL	20030128	MO	005004051	20030408
MO	005004052	AL	20030128	MO	005004052	20030408
MO	005004053	AL	20030128	MO	005004053	20030408
MO	005004054	AL	20030128	MO	005004054	20030408
MO	005004055	AL	20030128	MO	005004055	20030408
MO	005004056	AL	20030128	MO	005004056	20030408
MO	005004057	AL	20030128	MO	005004057	20030408
MO	005004058	AL	20030128	MO	005004058	20030408
MO	005004059	AL	20030128	MO	005004059	20030408
MO	005004060	AL	20030128	MO	005004060	20030408
MO	005004061	AL	20030128	MO	005004061	20030408
MO	005004062	AL	20030128	MO	005004062	20030408
MO	005004063	AL	20030128	MO	005004063	20030408
MO	005004064	AL	20030128	MO	005004064	20030408
MO	005004065	AL	20030128	MO	005004065	20030408
MO	005004066	AL	20030128	MO	005004066	20030408
MO	005004067	AL	20030128	MO	005004067	20030408
MO	005004068	AL	20030128	MO	005004068	20030408
MO	005004069	AL	20030128	MO	005004069	20030408
MO	005004070	AL	20030128	MO	005004070	20030408
MO	005004071	AL	20030128	MO	005004071	20030408
MO	005004072	AL	20030128	MO	005004072	20030408
MO	005004073	AL	20030128	MO	005004073	20030408
MO	005004074	AL	20030128	MO	005004074	20030408
MO	005004075	AL	20030128	MO	005004075	20030408
MO	005004076	AL	20030128	MO	005004076	20030408
MO	005004077	AL	20030128	MO	005004077	20030408
MO	005004078	AL	20030128	MO	005004078	20030408
MO	005004079	AL	20030128	MO	005004079	20030408
MO	005004080	AL	20030128	MO	005004080	20030408
MO	005004081	AL	20030128	MO	005004081	20030408
MO	005004082	AL	20030128	MO	005004082	20030408
MO	005004083	AL	20030128	MO	005004083	20030408
MO	005004084	AL	20030128	MO	005004084	20030408
MO	005004085	AL	20030128	MO	005004085	20030408
MO	005004086	AL	20030128	MO	005004086	20030408
MO	005004087	AL	20030128	MO	005004087	20030408
MO	005004088	AL	20030128	MO	005004088	20030408
MO	005004089	AL	20030128	MO	005004089	20030408
MO	005004090	AL	20030128	MO	005004090	20030408
MO	005004091	AL	20030128	MO	005004091	20030408
MO	005004092	AL	20030128	MO	005004092	20030408
MO	005004093	AL	20030128	MO	005004093	20030408
MO	005004094	AL	20030128	MO	005004094	20030408
MO	005004095	AL	20030128	MO	005004095	20030408
MO	005004096	AL	20030128	MO	005004096	20030408
MO	005004097	AL	20030128	MO	005004097	20030408
MO	005004098	AL	20030128	MO	005004098	20030408
MO	005004099	AL	20030128	MO	005004099	20030408

OTHER SOURCE(S):
 GE NARPAT 139:323539




^{AB} Novel hydroxamic acid derivs., e.g., I [X = null or CS₂; Z = CS₂, O, S,

16 ANSWER 3 OF 7 CAPLOS COPYRIGHT 2009 ACS on STN (Continued)



C02 1-Piperidinebutanamide, N-hydroxy- β -(4-methoxyphenyl)-2-[
[methylanilino]oxycarbonyl]- γ -oxo- α -(phenylmethoxy)methyl]-,
[R,R,2S,2S]-(CA INDEX NAME)

Absolute stereochemistry.



IT	62026-83-6P	62240-59-3P	62240-59-3P
	62840-61-6P	62840-64-9P	62840-66-1P
	62840-67-2P	62840-68-3P	62840-69-4P
	62840-70-7P	62840-71-9P	62840-72-1P
	62840-74-3P	62840-74-3P	62840-75-5P
	62840-76-3P	62840-77-6P	62840-78-5P
	62840-79-6P		
RL	PAC (Pharmaceutical activity); SPN (Synthetic preparation); TWU (Therapeutic use); BLOL (Biological study); PREP (Preparation); USES (Uses)		

[preparation of hydroxamic acid derivs. for use as pharmaceuticals]
 321 611034-83-6 CAPLOS
 CN 1-Piperidinebutanamide, β -(4-chlorophenyl)- α -ethyl-N-hydroxy-2-
 [[[(1-methylethyl)amino]carbonyl]-y-oxo-, (2S,3S,3S)- (CA
 1998, 114491)

Absolute Stereochemistry

1:6 MEMBER 3 OF 77 CAPSULE COPYRIGHT 2009 ACS on EYU (Continued)

or derivs. R1 = (m)substituted alkyl, cycloalkyl, heterocycloalkyl or aryl; R2 = H, C6H5,7-Q-8R, CO-Q-8R, CS-Q-8R, where R6, R7 = groups given for R1 and R8 = (m)substituted alkyl, cycloalkyl, aryl, or arylalkyl;


R3, R4 = R or alkyl; R5 = halo, cyano, alkyl, haloalkyl, aryl, CE, etc., where

prepared, for use as pharmaceuticals, e.g., for the suppression of THF release and the treatment of autoimmune and inflammatory diseases, e.g., multiple sclerosis and rheumatoid arthritis. Thus,

315) (4-chlorophenyl)-(2S)-(2S)-2-hydroxy-4-morpholino-4-methyltriazide was prepd. by reacting 4-chlorophenyl-(2S)-(2S)-2-hydroxy-4-methyltriazide with morpholine followed by NaOH , see, e.g., the double

17	<p>and hydroxylation. Compds. of the invention suppress TRF release with an IC50 of approx. 50 nM to approx. 5 μM and inhibit collagenase at concs. < 10 nM.</p> <p>Ex: 621940-60-5P 621940-62-7P 621940-65-0P</p> <p>Mo: FMC (Pharmaceutical activity); ECT (Reactant); SYN (Synthetic preparation); TRF (Therapeutic use); BIOG. (Biological study); PREP (Preparation); TRF (Reactant); TRF (Reactant); TRF (Reactant); TRF (Preparation of hydrozoic acid derivative for use as pharmaceuticals).</p>
18	<p>621940-60-5 CAPLOS</p>
19	<p>2-[piperidin-2-yl]-N-hydroxy-3-[4-(methoxycarbonyl)-p-oxo-5-phenylmethoxy]methyl-, (as salt) - (CA INDEX NAME)</p>

Absolute stereochemistry




HN 612840-62-7 CAPLUS
 CN 1-Piperazinecarboxylic acid, 4-[(2S,3S)-2-(4-chlorophenyl)-3-

[(hydroxyamino)carbonyl]-1-oxopentyl]-3-[[(2-methylpropyl)amino]carbonyl]-
1,1-dimethylethyl ester. (3S)- (CA INDEX NAME)


Absolute stereochemistry.

LE ANSWER 3 OF 7 CAPLOS COPYRIGHT 2009 ACS on STN (Continued)




RXN E12840-53-1 CAPLUS
 CN 4-Morpholinebutanamide, β -(4-chlorophenyl)- α -ethyl-N-hydroxy-
 γ -exo-, (4S,5S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 612840-59-2 CAPLUS
 CN 1-Piperazinebutananide, 6-(4-chlorophenyl)-N-hydroxy- β -(4-methoxyphenyl)- γ -oxo- α -[(phenylmethoxy)methyl]-, (e.f. 88)- (CA INDEX NAME)


Absolute stereochemistry



EN 612840-61-6 CAPLOS
CN 1-Piperidinebutanamide, N-hydroxy- ω -(hydroxymethyl)- β -(4-nethoxyphenyl)- γ -oxo-, (aR, β R)- (CA INDEX NAME)


16 ANWER 3 OF 7 CAPLOS COPYRIGHT 2009 ACS ON STM (Continued)
 EN 61840-79-2 CAPLOS
 CN 1-Pyrrolidinemethanamide, β -(4-chlorophenyl)- α -ethyl-N-hydroxy-2-
 -[[1-methyl-4-hydroxypropylamino]carbonyl]- γ -oxo-, (4S,6S,2S)- (CA INDEX NAME)
 (4S,6S,2S)- (CA INDEX NAME)

Absolute stereochemistry.




EN 61840-76-3 CAPLOS
 CN 2-Pyridylidenebutanamide, β -(4-chlorophenyl)- α -ethyl-N-hydroxy- γ -oxo-2-[[1-methyl-4-hydroxypropylamino]carbonyl]-, (4S,6S,2S)- (CA INDEX NAME)
 (4S,6S,2S)- (CA INDEX NAME)

Absolute stereochemistry.



EN 61840-77-4 CAPLOS
 CN 1-Pyrrolidinemethanamide, β -(4-chlorophenyl)- α -ethyl-N-hydroxy- γ -oxo-2-[[1-methyl-4-hydroxypropylamino]carbonyl]-, (4S,6S,2S)- (CA INDEX NAME)
 (4S,6S,2S)- (CA INDEX NAME)

Absolute stereochemistry.



16 ANWER 4 OF 7 CAPLOS COPYRIGHT 2009 ACS ON STM (Continued)
 ACCESSION NUMBER: 2003:513389 CAPLOS
 DOCUMENT NUMBER: 139352567
 TITLE: Methods for the treatment of chronic pain with NMDA
 INVENTOR(S): Branton, Francois; Kelly, Fox, Alyson; Gao, Jia; Panosch,
 Gray, Andrew J.; Song, Chuanzhong; Urban, Laszlo
 PATENT ASSIGNOR(S): Novartis A.G.; Novartis, Novartis Pharma G.m.b.H.
 SOURCE: PCT Int. Appl., 45 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION: 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003/04540	A2	20031016	WO 2003/04540	20030408
WO 2003/04540	A3	20040408		
W	AK, AG, AL, AM, AN, AT, AU, AZ, BA, BB, BG, BR, BY, BE, CA, CH, CN, CO, CP, CZ, DE, DK, DM, DO, EC, EE, ES, FI, GB, GR, HK, HU, IL, IN, JP, KR, KZ, LG, LU, LV, MA, MD, ME, MG, MK, MN, MU, MV, MY, NZ, PA, PE, PG, PH, PL, PT, RO, RU, SC, SE, SG, SI, SK, SL, SM, SN, SR, TH, TM, TW, UA, UG, US, VC, VN, WO, ZA, ZM, ZW			
MM, ME, AE, BF, BG, BR, BY, CA, CH, CN, CO, CP, CZ, DE, DK, DM, DO, EC, EE, ES, FI, GB, GR, HK, HU, IL, IN, JP, KR, KZ, LG, LU, LV, MA, MD, ME, MG, MK, MN, MU, MV, MY, NZ, PA, PE, PG, PH, PL, PT, RO, RU, SC, SE, SG, SI, SK, SL, SM, SN, SR, TH, TM, TW, UA, UG, US, VC, VN, WO, ZA, ZM, ZW				
NO 2003/04540	A3	20031009	NO 2003-22455	20030408
EP 1494301	A2	20050319	EP 2003-72437	20030408
AT, AU, BE, CH, CN, DE, ES, FI, GB, GR, IT, IL, JP, KR, LU, MA, MD, ME, MG, MK, MN, MU, MV, MY, NZ, PA, PE, PG, PH, PL, PT, RO, RU, SC, SE, SG, SI, SK, SL, SM, SN, SR, TH, TM, TW, UA, UG, US, VC, VN, WO, ZA, ZM, ZW				
JP 2005248220	T	20050908	JP 2003-581780	20030408
US 20050179323	A1	20050908	US 2003-510300	20030413
PRIORITY APPL. (TRIP.)			US 2002-371042P	P 20020408
			WO 2003-04540	M 20030408


AB The invention discloses NMDA as a suitable target for the development of new therapeutics to treat or ameliorate chronic pain. The invention relates to methods to treat and/or ameliorate chronic pain and pharmacological compounds, therefore comprising modulators with inhibitory effect on NMDA receptor activity and/or NMDA gene expression. The invention also relates to a method to identify compounds, with therapeutic usefulness to treat chronic pain, comprising identifying compounds, that can inhibit NMDA activity and/or gene expression which can also reverse the pathophysiological effects of chronic pain in vivo.

IC 61204-83-4
 RI: PKC (Pharmacological activity); TRP (Therapeutic use); RIGL (Biological study); ORES (Ores)
 (method for treatment of chronic pain with NMDA inhibitors)
 EN 61204-83-4 CAPLOS
 CN 1-Pyrrolidinemethanamide, β -(4-chlorophenyl)- α -ethyl-N-hydroxy-2-[[1-methyl-4-hydroxypropylamino]carbonyl]- γ -oxo-, (4S,6S,2S)- (CA INDEX NAME)

Absolute stereochemistry.


16 ANWER 3 OF 7 CAPLOS COPYRIGHT 2009 ACS ON STM (Continued)
 EN 61840-78-5 CAPLOS
 CN 1-Pyrrolidinemethanamide, α -ethyl-N-hydroxy- β -(4-methoxyphenyl)- γ -oxo-2-[[1-methyl-4-hydroxypropylamino]carbonyl]-, (4S,6S,2S)- (CA INDEX NAME)
 (4S,6S,2S)- (CA INDEX NAME)

Absolute stereochemistry.



EN 61204-79-4 CAPLOS
 CN 1-Pyrrolidinemethanamide, β -(4-chlorophenyl)- α -ethyl-N-hydroxy-2-[[1-methyl-4-hydroxypropylamino]carbonyl]- γ -oxo-, (4S,6S,2S)- (CA INDEX NAME)
 (4S,6S,2S)- (CA INDEX NAME)


Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE SE

FORMAT

16 ANWER 4 OF 7 CAPLOS COPYRIGHT 2009 ACS ON STM (Continued)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE SE

FORMAT

16 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2009 ACS ON STN

ACCESSION NUMBER: 1993;124420 CAPLUS

DOCUMENT NUMBER: 119;124430

ORIGINAL REFERENCE NO.: 119;21569a,21570a

TITLE: Reaction of carbonyl esters and carbonyl

derivatives

with dialkylated benzyl hydroxamate: a novel route

for synthesis of 1,2-oxazolones and

4,5-dihydro-1,2-oxazolones

M'abed, P.; Amor, A. Bel Hadj; Navor, R.

Lab. Synth. Org., Fac. Sci. Tunis, Tunis, 1060,

Tunisia

SOURCE: Journal de la Societe Chimique de Tunisie (1991),

119;124430

CODEN: JSCOTDPS ISSN: 0253-1208

Journal

French

DOCUMENT TYPE:

LANGUAGE:

OT



AS Lithiation of PhCH₂C(OR)NOR and reaction with RCOEt (R = H, Me, Et,

Ph)

gave RCH₂C(OR)NOR which were cyclized to isoxazolones 1. Isoxazolones

11 (R = H, Me, Et) 12 (R = Ph, 4-ClC₆H₄, Me, Et) were similarly obtained

from RCH₂CO and PhCH₂C(OR)NOR.

IT 146197-24-2F 146197-29-7F 146197-30-0F

146197-31-1F

Et: NCT (Reagent); SPN (Synthetic preparation); PREP (Preparation); RACT

(Reactant on reagent)

(Preparation and cyclization of)

PH 146197-34-3 CAPLUS

CH Benzenesulphanilic acid, N-hydroxy- α -(hydroxyphenylmethylene)-,

ethyl ester (CA INDEX NAME)



PH 146197-29-7 CAPLUS

CH Benzenesulphanilic acid, N, β -dihydroxy- α -phenyl-, ethyl ester

(CA INDEX NAME)



PH 146197-30-0 CAPLUS

CH Benzenesulphanilic acid, 6-chloro-N, β -dihydroxy- α -phenyl-,

16 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2009 ACS ON STN

ACCESSION NUMBER: 1993;105478 CAPLUS

DOCUMENT NUMBER: 99;5478

ORIGINAL REFERENCE NO.: 99;59a,1000a

TITLE: Preparation and reactions of

3,4-dihydro-2H-pyran-2-one

El-Kholi, Ibrahim El-Sayed; Miahikay, Morocco

Mohamaj

Abdel-Khalil, Salah Loufi

Fac. Sci., Alexandria Univ., Alexandria, Egypt

Journal of Heterocyclic Chemistry (1992), 19;16,

1129-34

CODEN: JHETCA; ISSN: 0022-152X

Journal

English

OTHER SOURCE(S): CASREACT 99;5478

OT



AS Michael reaction of 6-RCH₂CH₂COEt (R = H, MeO) with deoxybenzoin gave

4-RCH₂CH₂CH₂CH₂COEt which were hydrolyzed to the corresponding

acids. The latter could be cyclized to the dihydropyranones 1 (R = O)

which underwent ring opening with nucleophiles to give

4-RCH₂CH₂CH₂CH₂COEt (R = H, MeO, PhMe, MeOMe, ROME,

piperidino). However, their reaction with MeCO₂ gave 1 (R = NH). 1 (X

= O, NH) were dehydrogenated to 2-pyrones and 2-pyridones by fusion with

NaOMe.

IT 85503-41-3P 85503-42-2P


Et: SPN (Synthetic preparation); PREP (Preparation)

(Preparation of)

PH 85503-41-3 CAPLUS

CH Benzenesulphanilic acid, N-hydroxy-3-oxo- β , γ -diphenyl-,

(CA INDEX NAME)




PH 85503-42-0 CAPLUS

CH Benzenesulphanilic acid, N-hydroxy- β -(4-methoxyphenyl)-3-oxo- γ -

phenyl-, (CA INDEX NAME)

16 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2009 ACS ON STN (Continued)

ethyl ester (CA INDEX NAME)




PH 146197-31-1 CAPLUS

CH Benzenesulphanilic acid, N, β -dihydroxy- α -phenyl-,

ethyl ester (CA INDEX NAME)



16 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2009 ACS ON STN (Continued)



16 ABSTRACT OF ? CAPLUS COPYRIGHT 2009 ACS on STM
 ACCESSION NUMBER: 1968;86992 CAPLUS
 DOCUMENT NUMBER: 6816992
 ORIGINAL REFERENCE NO.: 6816751a;16754a
 TITLE: Electrochemical reduction of phenylglyoxal and phenylglyoxyhydrazonic acid
 AUTHOR(S): Armand, Joseph; Souchay, Pierre; Valentini, Françoise
 ORGANIZATIONAL SOURCE: Fac. Sci., Paris, Fr.
 SOURCE: Comptes Rendus des Seances de l'Academie des Sciences, Serie C: Sciences Chimiques (1967), 265(22), 1267-70
 DOCUMENT TYPE: Journal
 LANGUAGE: French
 AB: The electrochem. reduction of PhCOC(=O)NH2 at a Hg cathode gave 70% PhC(=O)C(=O)NH2.
 [I] and 50% pure diastereoisomeric diphenyltartramide (II), m. 223°. Chemical reduction of the starting compound gave only 70% I. Treatment of II with KOH followed by hydration gave PhC(=O)C(=O)NH2.
 Electrochem. reduction of PhCOC(=O)NH2 gave I and PhC(=O)C(=O)NH2, m. 223°. Chemical reduction of the hydrazonic acid with Zn and H2SO4 gave 70% I. The reaction mechanisms were discussed.
 22 1061527-64-20
 23 1061527-64-20
 24 1061527-64-20
 25 1061527-64-20
 26 1061527-64-20
 27 1061527-64-20
 28 1061527-64-20
 29 1061527-64-20
 30 1061527-64-20
 31 1061527-64-20
 32 1061527-64-20
 33 1061527-64-20
 34 1061527-64-20
 35 1061527-64-20
 36 1061527-64-20
 37 1061527-64-20
 38 1061527-64-20
 39 1061527-64-20
 40 1061527-64-20
 41 1061527-64-20
 42 1061527-64-20
 43 1061527-64-20
 44 1061527-64-20
 45 1061527-64-20
 46 1061527-64-20
 47 1061527-64-20
 48 1061527-64-20
 49 1061527-64-20
 50 1061527-64-20
 51 1061527-64-20
 52 1061527-64-20
 53 1061527-64-20
 54 1061527-64-20
 55 1061527-64-20
 56 1061527-64-20
 57 1061527-64-20
 58 1061527-64-20
 59 1061527-64-20
 60 1061527-64-20
 61 1061527-64-20
 62 1061527-64-20
 63 1061527-64-20
 64 1061527-64-20
 65 1061527-64-20
 66 1061527-64-20
 67 1061527-64-20
 68 1061527-64-20
 69 1061527-64-20
 70 1061527-64-20
 71 1061527-64-20
 72 1061527-64-20
 73 1061527-64-20
 74 1061527-64-20
 75 1061527-64-20
 76 1061527-64-20
 77 1061527-64-20
 78 1061527-64-20
 79 1061527-64-20
 80 1061527-64-20
 81 1061527-64-20
 82 1061527-64-20
 83 1061527-64-20
 84 1061527-64-20
 85 1061527-64-20
 86 1061527-64-20
 87 1061527-64-20
 88 1061527-64-20
 89 1061527-64-20
 90 1061527-64-20
 91 1061527-64-20
 92 1061527-64-20
 93 1061527-64-20
 94 1061527-64-20
 95 1061527-64-20
 96 1061527-64-20
 97 1061527-64-20
 98 1061527-64-20
 99 1061527-64-20
 100 1061527-64-20



=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

44.48

241.95

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-5.74

-5.74

STN INTERNATIONAL LOGOFF AT 08:19:24 ON 17 APR 2009